Security Snapshot

Drugs Made In America Acquisition Corp. - Ordinary Shares, $0.0001 par value (DMAA) Institutional Ownership

CUSIP: G2847J104

13F Institutional Holders and Ownership History from Q1 2025 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

38

Shares (Excl. Options)

22,313,763

Price

$10.37

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Ordinary Shares, $0.0001 par value
Symbol
DMAA on Nasdaq
Shares outstanding
33,549,784
Price per share
$10.49
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
22,313,763
Total reported value
$231,075,647
% of total 13F portfolios
0%
Share change
+1,034,167
Value change
+$10,437,875
Number of holders
38
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • DMAA - Drugs Made In America Acquisition Corp. - Ordinary Shares, $0.0001 par value is tracked under CUSIP G2847J104.
  • 38 institutions reported positions in Q4 2025.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 38 to 38 between Q3 2025 and Q4 2025.
  • Reported value moved from $230,112,841 to $231,075,647.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 38 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP G2847J104?
CUSIP G2847J104 identifies DMAA - Drugs Made In America Acquisition Corp. - Ordinary Shares, $0.0001 par value in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Drugs Made In America Acquisition Corp. - Ordinary Shares, $0.0001 par value (DMAA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Drugs Made In America Acquisition LLC 12% $42,139,127 4,188,780 Drugs Made In America Acquisition LLC 18 Feb 2025
Karpus Management, Inc. 8.2% +18% $27,989,912 +$4,284,765 2,744,109 +18% KARPUS MANAGEMENT, INC. 30 Jun 2025
First Trust Capital Management L.P. 6.2% $20,791,022 2,066,702 First Trust Capital Management L.P. 31 Mar 2025
Polar Asset Management Partners Inc. 5.7% $19,114,000 1,900,000 Polar Asset Management Partners Inc. 31 Mar 2025
GLAZER CAPITAL, LLC 5.4% $18,338,897 1,822,952 Glazer Capital, LLC 31 Mar 2025
Hudson Bay Capital Management LP 4.6% -15% $15,918,500 -$2,567,500 1,550,000 -14% Hudson Bay Capital Management LP 30 Sep 2025

As of 31 Dec 2025, 38 institutional investors reported holding 22,313,763 shares of Drugs Made In America Acquisition Corp. - Ordinary Shares, $0.0001 par value (DMAA). This represents 67% of the company’s total 33,549,784 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Drugs Made In America Acquisition Corp. - Ordinary Shares, $0.0001 par value (DMAA) together control 64% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Karpus Management, Inc. 7.6% 2,538,642 -0.35% 0.81% $26,325,718
First Trust Capital Management L.P. 6.7% 2,242,500 0% 1.4% $23,264,144
Glazer Capital, LLC 5.4% 1,816,428 -0.32% 0.5% $18,836,000
Westchester Capital Management, LLC 5% 1,669,000 0% 0.81% $17,307,530
Polar Asset Management Partners Inc. 4.8% 1,600,000 -16% 0.33% $16,598,720
Hudson Bay Capital Management LP 4.6% 1,550,000 0% 0.09% $16,073,500
MIZUHO SECURITIES USA LLC 4.3% 1,433,483 +30% 0.24% $14,771,165
WOLVERINE ASSET MANAGEMENT LLC 3.9% 1,307,468 +4.7% 0.19% $13,563,935
ARISTEIA CAPITAL, L.L.C. 2.6% 881,716 0% 0.26% $9,147,098
Mercuria Capital Strategies, LLC 2.2% 750,000 4.3% $7,511,250
D. E. Shaw & Co., Inc. 2.1% 690,000 0% 0.01% $7,155,300
HEIGHTS CAPITAL MANAGEMENT, INC 1.9% 650,000 0% 2.6% $6,740,500
Radcliffe Capital Management, L.P. 1.6% 546,808 +3.5% 0.31% $5,673,133
LMR Partners LLP 1.5% 500,000 0% 0.05% $5,187,100
J. Goldman & Co LP 1.5% 500,000 0% 0.2% $5,187,100
RIVERNORTH CAPITAL MANAGEMENT, LLC 1.2% 417,998 +31% 0.2% $4,334,639
WHITEBOX ADVISORS LLC 1.2% 400,000 0% 0.07% $4,149,680
AQR Arbitrage LLC 1.1% 371,211 0% 0.08% $3,849,458
BOOTHBAY FUND MANAGEMENT, LLC 1% 346,154 -31% 0.1% $3,591,071
Quarry LP 0.79% 266,551 +1596% 0.67% $2,765,467
Context Capital Management, LLC 0.75% 250,000 0% 0.07% $2,593,550
Governors Lane LP 0.75% 250,000 +2132% 0.24% $2,593,750
Shaolin Capital Management LLC 0.6% 202,069 +35% 0.08% $2,096,304
TORONTO DOMINION BANK 0.6% 200,000 -56% 0% $2,074,800
L1 Global Manager Pty Ltd 0.6% 200,000 0% 1.4% $2,074,840

Institutional Holders of Drugs Made In America Acquisition Corp. - Ordinary Shares, $0.0001 par value (DMAA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 22,313,763 $231,075,647 +$10,437,875 $10.37 38
2025 Q3 22,407,322 $230,112,841 +$8,645,514 $10.27 38
2025 Q2 20,823,195 $212,304,432 +$35,784,995 $10.20 32
2025 Q1 16,949,502 $169,795,617 +$169,795,617 $10.02 23